Tang Rongrui, Shi Jiantao, Li Xuegang, Zou Yongjie, Wang Long, Chen Yujie, Yan Rubin, Gao Boyuan, Feng Hua
Department of Neurosurgery, Southwest Hospital, Army Medical University, Chongqing, China.
Department of Neurosurgery, No. 184 of PLA Hospital, Yingtan, China.
World Neurosurg. 2018 Sep;117:e425-e429. doi: 10.1016/j.wneu.2018.06.047. Epub 2018 Jun 18.
To investigate the effects of atorvastatin on the surgical treatment of patients with chronic subdural hematoma (CSDH).
Our retrospective study included 245 consecutive adult patients undergoing burr-hole craniotomy for CSDH. Data included baseline characteristics and recurrence, postoperative complications, and mortality. Univariate and multivariate regression models analyzed the association between administration of atorvastatin perioperatively and recurrence rates.
Multivariate analysis showed perioperative atorvastatin administration (odds ratio [OR] 0.336; P = 0.039), diabetes mellitus (OR 3.949, P = 0.010), and GCS of 15 preoperatively (OR 0.197; P = 0.020) to be significantly related to recurrence risk. Postoperative complications and mortality did not significantly differ between patients with and those without atorvastatin therapy.
Our findings demonstrate that the administration of atorvastatin perioperatively is associated with a lower risk of CSDH recurrence rate. The use of atorvastatin perioperatively was not associated with higher rates of morbidity or mortality.
探讨阿托伐他汀对慢性硬膜下血肿(CSDH)患者外科治疗的影响。
我们的回顾性研究纳入了245例连续接受钻孔开颅术治疗CSDH的成年患者。数据包括基线特征、复发情况、术后并发症及死亡率。单因素和多因素回归模型分析了围手术期使用阿托伐他汀与复发率之间的关联。
多因素分析显示,围手术期使用阿托伐他汀(比值比[OR] 0.336;P = 0.039)、糖尿病(OR 3.949,P = 0.010)以及术前格拉斯哥昏迷量表(GCS)评分为15分(OR 0.197;P = 0.020)与复发风险显著相关。接受阿托伐他汀治疗和未接受治疗的患者术后并发症及死亡率无显著差异。
我们的研究结果表明,围手术期使用阿托伐他汀与CSDH复发率降低相关。围手术期使用阿托伐他汀与更高的发病率或死亡率无关。